BeOne Medicines (ONC) director awarded 18,980 restricted units

Rhea-AI Filing Summary

Riva Alessandro reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. director Alessandro Riva received a grant of 18,980 ordinary shares in the form of restricted share units at no purchase price. These units vest on the earlier of the first anniversary of the grant date or the next annual general meeting, subject to his continued board service and potential accelerated vesting under the company’s Independent Non-Executive Director Compensation Policy. Following this award, Riva directly holds 73,164 ordinary shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Riva Alessandro

Role null

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,980	$0.00	--

Holdings After Transaction: Ordinary Shares — 73,164 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 18,980 shares Transaction price: $0.00 per share Post-grant holdings: 73,164 shares +1 more

4 metrics

RSU grant size 18,980 shares Restricted share units granted to director on 2026-06-11

Transaction price $0.00 per share Grant/award acquisition of ordinary shares

Post-grant holdings 73,164 shares Total ordinary shares held directly after transaction

Vesting trigger Earlier of first anniversary or next AGM Vesting condition for restricted share units

Key Terms

restricted share units, annual general meeting, Independent Non-Executive Director Compensation Policy, grant, award, or other acquisition

4 terms

restricted share units financial

"Represents securities underlying restricted share units."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

annual general meeting financial

"shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting"

Independent Non-Executive Director Compensation Policy financial

"unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy."

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Riva Alessandro

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		18,980	A	$0	73,164	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents securities underlying restricted share units. The restricted share units shall become fully vested on the earlier to occur of the first anniversary of the grant date or the date of the next annual general meeting; provided, however, that all vesting shall cease if the director resigns from the board of directors or otherwise ceases to serve as a director, unless there is a triggering event of accelerated vesting pursuant to the Company's Independent Non-Executive Director Compensation Policy.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did BeOne Medicines (ONC) report for Alessandro Riva?

BeOne Medicines reported that director Alessandro Riva received 18,980 ordinary shares through a restricted share unit grant at no purchase price. Following this equity award, his direct holdings increased to 73,164 ordinary shares in the company.

How many BeOne Medicines (ONC) shares did Alessandro Riva hold after this Form 4 grant?

After the reported restricted share unit grant, director Alessandro Riva directly held 73,164 ordinary shares of BeOne Medicines. This total includes the 18,980 shares represented by the newly granted restricted share units disclosed in the Form 4 filing.

What are the vesting terms of Alessandro Riva’s BeOne Medicines (ONC) restricted share units?

Riva’s restricted share units fully vest on the earlier of the first anniversary of the grant date or the next annual general meeting. Vesting stops if he ceases to serve as a director, unless accelerated under the Independent Non-Executive Director Compensation Policy.

Did Alessandro Riva buy BeOne Medicines (ONC) shares on the market in this Form 4?

No, the Form 4 shows a grant of 18,980 ordinary shares via restricted share units with a transaction price of zero. This is a compensation-related award, not an open-market purchase or sale of BeOne Medicines shares.

What does the transaction code on Alessandro Riva’s BeOne Medicines (ONC) Form 4 mean?

The transaction uses code “A,” indicating a grant, award, or other acquisition of securities. In this case, it reflects a compensation-related grant of restricted share units that represent 18,980 ordinary shares of BeOne Medicines to director Alessandro Riva.